Natilus and Palantir Announce Strategic Partnership to Accelerate Production of Sustainable Commercial Aircraft
Palantir's advanced AI-based operating system will supercharge Natilus's engineering, design and manufacturing as it rapidly scales U.S. production capabilities for blended-wing aircraft
SAN DIEGO, April 30, 2025 /PRNewswire/ — Natilus, an aerospace manufacturer of blended-wing-body aircraft, today announced a strategic partnership with Palantir Technologies Inc. to advance the production of sustainable aircraft in the U.S. Through the collaboration, Natilus and Palantir are deploying an AI-based operating system to accelerate the development of innovative approaches to design, engineering and manufacturing and streamline Natilus's operations and strengthen its supply chain.
In an era of critically constrained access to aircraft components, market demand for cargo and passenger aircraft is outpacing domestic manufacturing capabilities. With the aviation industry challenged to operate more sustainably, cargo and passenger airlines are eager to pursue more technologically advanced approaches to deliver elevated yet economical fleet operations.
To address the market demand, Natilus is developing a family of blended-wing-body aircraft for commercial operations. With an advanced carbon fiber airframe design, Natilus's family of aircraft includes a regional blended-wing-body freighter KONA, and a 200-passenger aircraft, the HORIZON, which both offer major advantages in fuel consumption, carbon emissions, and payload capacity.
'The U.S. desperately needs a boost in aircraft manufacturing, and Natilus is operating at the forefront of sustainable aircraft manufacturing,' said Aleksey Matyushev, Co-Founder and CEO of Natilus. 'We made a commitment to build the first manufacturing facility for the world's most efficient commercial aircraft here in the U.S. Our success hinges on accelerating our production capabilities, and leveraging Palantir's AI-driven platform will allow us to transform our manufacturing operations to run more efficiently and meet customer demand for the cargo and passenger markets.'
Natilus is deploying Palantir Warp Speed for its operations, providing AI-driven data, analytics and modeling to drive real-time decision making. Through the collaboration, Natilus will initially focus on increasing supply chain resiliency and manufacturing efficiency, and further down the line, offering its cargo and passenger customers key insights to enable predictive maintenance, disruption recovery and capture real-time aircraft performance data for product optimization.
'Natilus is delivering the future of sustainable aircraft, and we are extremely proud of deploying software that supports the sustained competitive advantage of their blended-wing-body aircraft,' said Emily Nguyen, Head of Industrials at Palantir. 'By providing the foundation on which Natilus will integrate all aspects of their aircraft design, engineering and manufacturing, Palantir is committed to helping Natilus build faster and strengthen the U.S.'s position in the global aviation landscape.'
About NatilusNatilus is a San Diego-based company developing a family of hyper-efficient blended-wing-body (BWB) aircraft designed to transport people and cargo more sustainably and efficiently than ever before. Natilus's BWB aircraft unlock improved aviation economics by reducing fuel consumption by 30% while increasing payload capability by 40%. Founded in 2016, the Natilus team is comprised of innovators from General Atomics, Northrop Grumman, Skunkworks, SpaceX, and Piper Aircraft. Learn more at natilus.co.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
38 minutes ago
- Malaysian Reserve
Shiji Releases 2025 Hospitality Distribution Technology Chart: Navigating a Rapidly Evolving Ecosystem
Consolidation, AI, social media booking, and direct channel growth define the next era of hotel distribution. BARCELONA, Spain, June 11, 2025 /PRNewswire/ — Shiji, the global hospitality technology innovator, today announced the launch of its 2025/2026 Hospitality Distribution Technology Chart, offering the industry's most up-to-date visual guide to the ever-changing world of hotel distribution. Now in its tenth year, the annual chart has become a trusted reference for hoteliers, investors, and tech providers seeking clarity in a crowded and complex technology landscape. The 2025/2026 edition captures a year defined by market consolidation, social media's rise as a direct booking channel, and a new wave of AI-powered, API-friendly solutions. A Snapshot of the New Distribution Reality From new players to evolving categories, the chart reflects key shifts in how hospitality companies connect with travelers across channels. The 2025 update introduces three new sections: Marketplace, Social Media with Booking, and Upselling. These additions highlight the growing influence of non-traditional booking paths and revenue opportunities. Meanwhile, a surge in brand evolutions and strategic acquisitions continues to reshape competitive dynamics. Key Trends Identified in the 2025/2026 Chart Include: The emergence of Marketplace platforms as important distribution avenues. Social media evolving from an inspiration tool to a booking engine. Upselling solutions becoming central to revenue strategy. AI integration across nearly every category of hotel technology. A shift toward end-to-end platforms delivering unified experiences. Growing emphasis on direct booking performance and ownership. Demand for open APIs and interoperable systems as hotels seek flexibility. The Rise of Social and Alternative Booking Paths For the first time, platforms like Douyin (TikTok China) and WeChat appear on the chart in a new 'Social Media with booking' category, acknowledging the growing role of social commerce in travel decisions. Likewise, the 'Marketplace' section spotlights new platforms giving hotels more distribution options outside traditional OTAs. Technology that Drives Revenue and Flexibility Hotels continue to invest in tech that delivers clear ROI, whether through smarter upselling, better direct booking performance, or enhanced business analytics tools. Open APIs and flexible integrations are no longer just nice to have; they are mission critical. An Industry Compass 'The hotel distribution landscape is evolving faster than ever,' said Natalie Kimball, Vice President of Strategic Accounts for Americas and EMEA at Shiji Horizon Distribution. 'Our 2025/2026 chart helps hoteliers make sense of that evolution by tracking not just the companies involved, but the trends shaping their decisions.' The Shiji Hospitality Distribution Technology Chart was first launched in 2015 and is curated with input from independent experts and hospitality stakeholders worldwide. It is freely available for download and widely used by hotel brands, consultants, and media. To download the full 2025/2026 chart and accompanying industry analysis, click here: Hotel Distribution Technology Chart 2025/2026 About Shiji Shiji is a multi-national technology company that provides software solutions and services for enterprise companies in the hospitality, food service, retail, and entertainment industries, ranging from hospitality technology platforms, hotel property management solutions, food and beverage and retail systems, payment gateways, data management, online distribution, and more. Founded in 1998 as a network solutions provider for hotels, Shiji today comprises over 5,000 employees in 80+ subsidiaries and brands in over 31 countries, serving more than 91,000 hotels, 200,000 restaurants, and 600,000 retail outlets. For more information, visit Media Contact:Gabriella Alverio AlborsMarketing Manager, AmericasShiji (404) 948 – 4001
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, 'This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible.' [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Sumsub Upgrades Case Management Solution with AI Assistant for FinCrime Teams
LONDON, June 10, 2025 /PRNewswire/ — Sumsub, a global verification leader, has announced a major AI-powered update to its Case Management solution—a ready-to-use, cross-functional hub for financial crime investigations designed to streamline fragmented risk operations. Built with direct input from fincrime teams and Sumsub clients, the new release introduces AI-driven tools and intelligent automation to help investigators act on risk in real time. The new Case Management solution provides a unified workspace for cross-functional teams, centralizing identity information, payment histories, risk scores, and internal audit notes in one intelligent interface. One of the key features of this upgrade is Summy, Sumsub's new AI Assistant, which provides case summaries and action recommendations for risk, compliance, and fraud teams. Summy gives investigators the full context of each case—covering user background, transaction history, behavioral insights, and more—while suggesting smart next steps to accelerate decision-making. Case Management is included as a core feature across Sumsub's identity verification, anti-fraud, and AML solutions—fully integrated and ready to deploy without complex adoption procedures. This launch comes as financial crime teams face increasingly complex threats. The global average fraud rate surged by 30% year-over-year—from 2.0% in 2024 to 2.6% in 2025 – driven by deepfakes, fraud-as-a-service, and rapidly evolving typologies. Teams must act faster, smarter, and more collaboratively than ever before. Apart from Summy, AI assistant key features include: Pre-built, customizable workflow templates ('Case Blueprints') that can be set up and used straight away Unified access to applicant data, documents, AML flags, and payments—removes silos and accelerates investigations Custom case views and role-based access control tailors visibility of data and sensitive information, with ability to easily move responsibilities and access around team members Real-time risk updates ensure every decision reflects the latest user behavior and transaction patterns Fraud Network Detection uses AI to uncover hidden connections between suspicious users and real–behaviors 'Fragmentation is one of the biggest threats in modern risk management,' said Andrew Novoselsky, Chief Product Officer at Sumsub. 'With the rise of deepfakes and complex fraud schemes, teams can't afford to work in silos. That's why we built a platform that's not just unified, but smart—where AI like Summy supports every step of the investigation. This is a leap forward in making compliance faster, clearer, and more effective. Tested extensively by Sumsub's Quality Control Team, and built on extensive research into fincrime teams and insights gathered during our Customer Advisory Board meetings, this solution was built to address the most pressing challenges in case management. It makes investigations faster, more transparent, and easier to manage for fraud and risk professionals.' To explore the new Case Management solution, visit: About Sumsub Sumsub is a full-cycle verification platform that secures the whole user journey. With Sumsub's customizable KYC, KYB, Transaction Monitoring, and Fraud Prevention solutions, you can orchestrate your verification process, welcome more customers worldwide, meet compliance requirements, reduce costs, and protect your business. Sumsub has over 4,000 clients across the fintech, crypto, transportation, trading, e-commerce, education, and gaming industries, including Bitpanda, Wirex, Avis, Bybit, Vodafone, Duolingo, Kaizen Gaming, and TransferGo. Sumsub has citations in research published by global institutions such as the United Nations and Statista, as well as ongoing consultancy and engagements with INTERPOL.
